Towards vaccine against toxoplasmosis: evaluation of the immunogenic and protective activity of recombinant ROP5 and ROP18 Toxoplasma gondii proteins.
Toxoplasmosis is one of the most common parasitic infections worldwide. An effective vaccine against human and animal toxoplasmosis is still needed to control this parasitosis. The polymorphic rhoptry proteins, ROP5 and ROP18, secreted by Toxoplasma gondii during the invasion of the host cell have been recently considered as promising vaccine antigens, as they appear to be the major determinants of T. gondii virulence in mice. The goal of this study was to evaluate their immunogenic and immunoprotective activity after their administration (separately or both recombinant proteins together) with the poly I:C as an adjuvant. Immunization of BALB/c and C3H/HeOuJ mice generated both cellular and humoral specific immune responses with some predominance of IgG1 antibodies. The spleen cells derived from vaccinated animals reacted to the parasite's native antigens. Furthermore, the immunization led to a partial protection against acute and chronic toxoplasmosis. These findings confirm the previous assumptions about ROP5 and ROP18 antigens as valuable components of a subunit vaccine against toxoplasmosis.
Department of Immunoparasitology, Faculty of Biology and Environmental Protection, University of Łódź, Łódź, Poland. margrzy@gmail.com.
Marcin M
MM
Grzybowski
Department of Immunoparasitology, Faculty of Biology and Environmental Protection, University of Łódź, Łódź, Poland.
Bożena
B
Dziadek
Department of Immunoparasitology, Faculty of Biology and Environmental Protection, University of Łódź, Łódź, Poland.
Justyna M
JM
Gatkowska
Department of Immunoparasitology, Faculty of Biology and Environmental Protection, University of Łódź, Łódź, Poland.
Katarzyna
K
Dzitko
Department of Immunoparasitology, Faculty of Biology and Environmental Protection, University of Łódź, Łódź, Poland.
Henryka
H
Długońska
D000818:Animals; D000913:Antibodies, Protozoan / Q000276:immunology; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D017346:Protein Serine-Threonine Kinases / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D015800:Protozoan Proteins; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D013154:Spleen / Q000276:immunology; D014122:Toxoplasma / Q000235:genetics / Q000276:immunology*; D014123:Toxoplasmosis / Q000276:immunology / Q000469:parasitology / Q000517:prevention & control*; D014611:Vaccination; D014612:Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology
D000913:Antibodies, Protozoan; D015800:Protozoan Proteins; D011994:Recombinant Proteins; D014612:Vaccines; D022223:Vaccines, Subunit; D017346:Protein Serine-Threonine Kinases; C556793:ROP18 protein, Toxoplasma gondii
Immunoprophylaxis; ROP18 protein; ROP5 protein; Subunit vaccines; Toxoplasmosis